Your browser doesn't support javascript.
loading
Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
Xu, Jinping; Bock, Cathryn H; Janisse, James; Woo, Justin; Cher, Michael L; Ginsburg, Kevin; Yacoub, Rami; Goodman, Michael.
Afiliación
  • Xu J; Department of Family Medicine and Public Health Sciences, School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • Bock CH; Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • Janisse J; Department of Family Medicine and Public Health Sciences, School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • Woo J; Department of Family Medicine and Public Health Sciences, School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • Cher ML; Department of Urology, School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • Ginsburg K; Department of Urology, School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • Yacoub R; Department of Epidemiology, School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Goodman M; Department of Epidemiology, School of Public Health, Emory University, Atlanta, Georgia, USA.
Cancer ; 130(10): 1797-1806, 2024 May 15.
Article en En | MEDLINE | ID: mdl-38247317
ABSTRACT

BACKGROUND:

Active surveillance (AS) is the preferred strategy for low-risk prostate cancer (LRPC); however, limited data on determinants of AS adoption exist, particularly among Black men.

METHODS:

Black and White newly diagnosed (from January 2014 through June 2017) patients with LRPC ≤75 years of age were identified through metro-Detroit and Georgia population-based cancer registries and completed a survey evaluating factors influencing AS uptake.

RESULTS:

Among 1688 study participants, 57% chose AS (51% of Black participants, 61% of White) over definitive treatment. In the unadjusted analysis, patient factors associated with initial AS uptake included older age, White race, and higher education. However, after adjusting for covariates, none of these factors was significant predictors of AS uptake. The strongest determinant of AS uptake was the AS recommendation by a urologist (adjusted prevalence ratio, 6.59, 95% CI, 4.84-8.97). Other factors associated with the decision to undergo AS included a shared patient-physician treatment decision, greater prostate cancer knowledge, and residence in metro-Detroit compared with Georgia. Conversely, men whose decision was strongly influenced by the desire to achieve "cure" or "live longer" with treatment and those who perceived their LRPC diagnosis as more serious were less likely to choose AS.

CONCLUSIONS:

In this contemporary sample, the majority of patients with newly diagnosed LRPC chose AS. Although the input from their urologists was highly influential, several patient decisional and psychological factors were independently associated with AS uptake. These data shed new light on potentially modifiable factors that can help further increase AS uptake among patients with LRPC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Espera Vigilante Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Aged / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Espera Vigilante Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Aged / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...